1. Medtech Insight
  2. >>Archive

Advanced BioHealing adds $4.5m to second tranche of series C:

Advanced BioHealing (ABH), of La Jolla, California, closed its second tranche of series C financing after securing $4.5m from Safeguard Scientifics and CDIB BioScience Ventures. The regenerative medicine products developer has raised a total $30m in this round; the first $25.5m tranche took place in February 2007 (see Clinica No 1247, p 32). The company will use the funds to expand commercialisation of its Dermagraft wound healing technology in the US, and to help it pursue additional product opportunities. Clinical trials of ABH's newest technology Celaderm, a bioengineered venous leg ulcers treatment product, is currently at the patient enrolment stage.

Advanced BioHealing (ABH), of La Jolla, California, closed its second tranche of series C financing after securing $4.5m from Safeguard Scientifics and CDIB BioScience Ventures. The regenerative medicine products developer has raised a total $30m in this round; the first $25.5m tranche took place in February 2007 (see Clinica No 1247, p 32). The company will use the funds to expand commercialisation of its Dermagraft wound healing technology in the US, and to help it pursue additional product opportunities. Clinical trials of ABH's newest technology Celaderm, a bioengineered venous leg ulcers treatment product, is currently at the patient enrolment stage.

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Under Pressure: How To Safeguard The EU Responsible Person

 
• By Amanda Maxwell

The roles and responsibilities of EU medtech’s persons responsible for regulatory compliance vary widely in role and risk exposure. The recent TEAM-PRRC meeting highlighted how vulnerable they can be and the steps to protect themselves.

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Philips Ramps Up US Production, Seeks To Swiftly Move On From New FDA Warning Letter

 
• By Shubham Singh

Philips puts its latest “disappointing” warning letter into context, while announcing progress in regulatory performance, expanded US production and tariff resilience plans